{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:48:08Z","timestamp":1791748088080,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Sobi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.blre.2026.101432","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:01:57Z","timestamp":1788537717000},"page":"101432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequencing CD19-targeted therapies in patients with relapsed\/refractory large B-cell lymphoma: A narrative review"],"prefix":"10.1016","author":[{"given":"Paolo F.","family":"Caimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Melody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101432_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/j.blre.2026.101432_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"10.1016\/j.blre.2026.101432_bb0020","first-page":"4906","article-title":"Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies","volume":"49","author":"Press","year":"1989","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.blre.2026.101432_bb0025","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood.2024027347","article-title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study","volume":"145","author":"Chavez","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101432_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101002","article-title":"Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: other modes of transportation","volume":"57","author":"Sermer","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101432_bb0035","author":"IQVIA Institute for Human Data Science"},{"issue":"4","key":"10.1016\/j.blre.2026.101432_bb0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.blre.2026.101432_bb0060","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0065","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2026.101432_bb0070","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2023.283459","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.blre.2026.101432_bb0075","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2026.101432_bb0080","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101432_bb0085","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101432_bb0090","series-title":"Prescribing information","author":"Breyanzi","year":"2025"},{"issue":"10254","key":"10.1016\/j.blre.2026.101432_bb0095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2026.101432_bb0110","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101432_bb0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oncolo\/oyac256","article-title":"Clinical treatment guidelines for tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Nedved","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70256","article-title":"A real-world study of tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma in the United States","volume":"7","author":"Saverno","year":"2026","journal-title":"eJHaem"},{"issue":"26","key":"10.1016\/j.blre.2026.101432_bb0125","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12248-021-00660-3","article-title":"Efficacy and safety exposure-response analysis of loncastuximab tesirine in patients with B cell non-Hodgkin lymphoma","volume":"24","author":"Hess","year":"2021","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.blre.2026.101432_bb0135","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3324\/haematol.2024.285977","article-title":"Loncastuximab in high-risk and heavily pretreated relapsed \/ refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers","volume":"110","author":"Zelikson","year":"2025","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2026.101432_bb0140","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00262-022-03165-w","article-title":"Tafasitamab mediates killing of B-cell non-Hodgkin\u2019s lymphoma in combination with gammadelta T cell or allogeneic NK cell therapy","volume":"71","author":"Her","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2026.101432_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211027458","article-title":"The use of tafasitamab in diffuse large B-cell lymphoma","volume":"12","author":"Dull","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"19","key":"10.1016\/j.blre.2026.101432_bb0150","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2026.101432_bb0155","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101432_bb0160","series-title":"Prescribing information","author":"Monjuvi","year":"2025"},{"key":"10.1016\/j.blre.2026.101432_bb0165","series-title":"Prescribing information","author":"Zynlonta","year":"2026"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101432_bb0170","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1182\/blood-2022-159626","article-title":"CD19 expression by IHC alone is not a predictor of response to loncastuximab tesirine: results from the LOTIS-2 clinical trial and quantitative systems pharmacology modeling","volume":"140","author":"Caimi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jha2.816","article-title":"In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine","volume":"5","author":"Caimi","year":"2023","journal-title":"eJHaem"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70015","article-title":"Clinical impact of CD19 expression assessed by quantitative PCR in lymphoma patients undergoing CAR-T therapy","volume":"6","author":"Hernani","year":"2025","journal-title":"eJHaem"},{"issue":"14","key":"10.1016\/j.blre.2026.101432_bb0185","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-23-1962","article-title":"Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma","volume":"30","author":"Lownik","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2026.101432_bb0190","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.blre.2026.101432_bb0195","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101432_bb0200","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e19050","article-title":"CD19 expression in diffuse large B-cell lymphoma (DLBCL) patient biopsies after treatment with tafasitamab","volume":"42","author":"Volgina","year":"2024","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2026.101432_bb0205","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2026.101432_bb0210","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101432_bb0215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2025-957","article-title":"Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: a cell therapy consortium real world experience","volume":"146","author":"Zhang","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2026.101432_bb0220","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","article-title":"Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy","volume":"8","author":"Camus","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-024-00706-6","article-title":"Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma","volume":"13","author":"Epperla","year":"2025","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0230","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0235","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/10428194.2021.1986219","article-title":"CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study","volume":"63","author":"Duell","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101432_bb0240","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood-2023-182204","article-title":"Outcomes of sequential CD19-directed therapies in relapsed and refractory large B cell lymphoma","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2026.101432_bb0245","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.blre.2026.101432_bb0255","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.2022018905","article-title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS","volume":"143","author":"Sakemura","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101432_bb0315","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/jha2.993","article-title":"Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine","volume":"5","author":"Hamadani","year":"2024","journal-title":"eJHaem"},{"issue":"5","key":"10.1016\/j.blre.2026.101432_bb0365","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0340","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41408-024-01195-4","article-title":"Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"14","author":"Epperla","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0370","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","article-title":"Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy","volume":"59","author":"Iqbal","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0260","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.blre.2026.101432_bb0265","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"issue":"S3","key":"10.1016\/j.blre.2026.101432_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971432.07109.dc","article-title":"P1134: bispecific antiCD20\/19 CAR-T \u2013 zamtocabtagene autoleucel for relapsed\/refractory DLBCL \u2013 interim analysis results of DALY-II-USA study","volume":"7","author":"Shah","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.blre.2026.101432_bb0275","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/hematology.2024000667","article-title":"Sequencing bispecific antibodies and CAR T cells for FL","volume":"2024","author":"Russler-Germain","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2026.101432_bb0280","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1182\/blood-2023-186984","article-title":"Real-world analysis of barriers to timely administration of chimeric antigen receptor T-cell (CART) therapy in diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ehsan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101432_bb0285","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/bjh.70090","article-title":"Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma","volume":"207","author":"Morimoto","year":"2025","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101432_bb0290","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2026.101432_bb0295","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","article-title":"Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101432_bb0300","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2025-5515","article-title":"CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab","volume":"146","author":"Duell","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101432_bb0305","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2024-199176","article-title":"Maintenance of CD19 expression after tafasitamab treatment in patients with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) from clinical trial and real-world settings","volume":"144","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101432_bb0310","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","article-title":"Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma","volume":"46","author":"Jin","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"10.1016\/j.blre.2026.101432_bb0325","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10466","key":"10.1016\/j.blre.2026.101432_bb0330","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101432_bb0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e19537","article-title":"CD20 and CD19 expression loss in relapsed or refractory b-cell non-Hodgkin lymphoma: a retrospective cohort","volume":"40","author":"Marshalek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101432_bb0345","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1007\/s12325-020-01397-9","article-title":"A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible?","volume":"37","author":"Zhang","year":"2020","journal-title":"Adv Ther"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101432_bb0350","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1182\/blood-2022-155995","article-title":"Frontmind: a phase III, multicenter, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma","volume":"140","author":"Vitolo","year":"2022","journal-title":"Blood"},{"issue":"Supplement 17","key":"10.1016\/j.blre.2026.101432_bb0355","first-page":"LBA7000","article-title":"frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL)","volume":"44","author":"Lenz","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101432_bib371","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.blre.2026.101432_bb0360","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:25:06Z","timestamp":1791746706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":71,"alternative-id":["S0268960X26000718"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101432","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequencing CD19-targeted therapies in patients with relapsed\/refractory large B-cell lymphoma: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101432"}}